Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Self-reported health promotion and disability progression in multiple sclerosis.
Gateway to wellness: an occupational therapy collaboration with the national multiple sclerosis society.
Deliberate Fingolimod Overdose Presenting with Delayed Hypotension and Bradycardia Responsive to Atropine.
Treatment of Multiple Sclerosis With Chinese Scalp Acupuncture.
Evidence linking HHV-6 with multiple sclerosis: an update.
Viability of autoantibody-targets: How to tackle pathogenetic heterogeneity as an obstacle for treatment of multiple sclerosis.
A case of acute disseminated encephalomyelitis associated with hepatitis C virus infection.
Expanded Disability Status Scale (EDSS) estimation in multiple sclerosis from posturographic data.
The fraction of varicella zoster virus-specific antibodies among all intrathecally-produced antibodies discriminates between patients with varicella zoster virus reactivation and multiple sclerosis.
Multiple sclerosis fatigue relief by bilateral somatosensory cortex neuromodulation.
Speech and pause characteristics in multiple sclerosis: A preliminary study of speakers with high and low neuropsychological test performance.
Curcumin Serves as a Human Kv1.3 Blocker to Inhibit Effector Memory T Lymphocyte Activities.
An assay to quantify species-specific anti-JC virus antibody levels in MS patients.
A method for histopathological study of the multifocal nature of spinal cord lesions in murine experimental autoimmune encephalomyelitis.
Vitamin D levels and risk of multiple sclerosis in patients with clinically isolated syndromes.
A randomized clinical trial of autologous T-cell therapy in multiple sclerosis: subset analysis and implications for trial design.
Daclizumab for relapsing remitting multiple sclerosis.
Functional plasticity in MS: Friend or foe?
One-year Efficacy and Safety Results of Secukinumab in Patients With Rheumatoid Arthritis: Phase II, Dose-finding, Double-blind, Randomized, Placebo-controlled Study.
Discovery of Dual Leucine Zipper Kinase (DLK, MAP3K12) Inhibitors with Activity in Neurodegeneration Models.
Spatial modeling of multiple sclerosis for disease subtype prediction.
Spatial variability and changes of metabolite concentrations in the cortico-spinal tract in multiple sclerosis using coronal CSI.
The precise chemical-physical nature of the pharmacore in FK506 binding protein inhibition: ElteX, a new class of nanomolar FKBP12 ligands.
Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia.
HMGB1 in Development and Diseases of the Central Nervous System.

Pages